vs
碧迪（BDX）与NATIONAL HEALTHCARE CORP（NHC）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是NATIONAL HEALTHCARE CORP的13.6倍（$5.3B vs $386.5M）。碧迪净利率更高（7.3% vs 6.4%，领先0.8%）。NATIONAL HEALTHCARE CORP同比增速更快（4.6% vs -0.4%）。碧迪自由现金流更多（$549.0M vs $6.4M）。过去两年NATIONAL HEALTHCARE CORP的营收复合增速更高（14.0% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
HCA Healthcare是1968年成立的美国营利性医疗服务运营商，总部位于田纳西州纳什维尔。截至2020年5月，该公司在全美20个州及英国持有并运营186家医院，还有约2400个医疗服务网点，涵盖手术中心、独立急诊室、紧急护理中心及医师诊所，2024年位列美国财富500强第61位。
BDX vs NHC — 直观对比
营收规模更大
BDX
是对方的13.6倍
$386.5M
营收增速更快
NHC
高出5.0%
-0.4%
净利率更高
BDX
高出0.8%
6.4%
自由现金流更多
BDX
多$542.6M
$6.4M
两年增速更快
NHC
近两年复合增速
2.0%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $386.5M |
| 净利润 | $382.0M | $24.8M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 8.6% |
| 净利率 | 7.3% | 6.4% |
| 营收同比 | -0.4% | 4.6% |
| 净利润同比 | 24.0% | 308.6% |
| 每股收益（稀释后） | $1.34 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXNHC
| Q4 25 | $5.3B | $386.5M | ||
| Q3 25 | $5.9B | $382.7M | ||
| Q2 25 | $5.5B | $374.9M | ||
| Q1 25 | $5.3B | $373.7M | ||
| Q4 24 | $5.2B | $369.4M | ||
| Q3 24 | $5.4B | $340.2M | ||
| Q2 24 | $5.0B | $300.7M | ||
| Q1 24 | $5.0B | $297.2M |
净利润BDXNHC
| Q4 25 | $382.0M | $24.8M | ||
| Q3 25 | $493.0M | $39.2M | ||
| Q2 25 | $574.0M | $23.7M | ||
| Q1 25 | $308.0M | $32.2M | ||
| Q4 24 | $303.0M | $6.1M | ||
| Q3 24 | $400.0M | $42.8M | ||
| Q2 24 | $487.0M | $26.8M | ||
| Q1 24 | $537.0M | $26.2M |
毛利率BDXNHC
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXNHC
| Q4 25 | 10.5% | 8.6% | ||
| Q3 25 | 11.8% | 7.9% | ||
| Q2 25 | 16.0% | 9.1% | ||
| Q1 25 | 10.4% | 8.2% | ||
| Q4 24 | 8.8% | 7.8% | ||
| Q3 24 | 11.4% | 6.7% | ||
| Q2 24 | 12.1% | 7.5% | ||
| Q1 24 | 14.5% | 5.3% |
净利率BDXNHC
| Q4 25 | 7.3% | 6.4% | ||
| Q3 25 | 8.4% | 10.3% | ||
| Q2 25 | 10.4% | 6.3% | ||
| Q1 25 | 5.8% | 8.6% | ||
| Q4 24 | 5.9% | 1.6% | ||
| Q3 24 | 7.4% | 12.6% | ||
| Q2 24 | 9.8% | 8.9% | ||
| Q1 24 | 10.6% | 8.8% |
每股收益（稀释后）BDXNHC
| Q4 25 | $1.34 | $1.58 | ||
| Q3 25 | $1.71 | $2.50 | ||
| Q2 25 | $2.00 | $1.52 | ||
| Q1 25 | $1.07 | $2.07 | ||
| Q4 24 | $1.04 | $0.38 | ||
| Q3 24 | $1.37 | $2.73 | ||
| Q2 24 | $1.68 | $1.73 | ||
| Q1 24 | $1.85 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $92.8M |
| 总债务越低越好 | — | $40.0M |
| 股东权益账面价值 | $25.3B | $1.1B |
| 总资产 | $54.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.04× |
8季度趋势，按日历期对齐
现金及短期投资BDXNHC
| Q4 25 | $740.0M | $92.8M | ||
| Q3 25 | $641.0M | $130.6M | ||
| Q2 25 | $735.0M | $111.0M | ||
| Q1 25 | $667.0M | $90.4M | ||
| Q4 24 | $711.0M | $76.1M | ||
| Q3 24 | $1.7B | $84.8M | ||
| Q2 24 | $4.5B | $136.2M | ||
| Q1 24 | $2.3B | $94.0M |
总债务BDXNHC
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $73.1M | ||
| Q2 25 | — | $110.0M | ||
| Q1 25 | — | $134.0M | ||
| Q4 24 | — | $137.0M | ||
| Q3 24 | — | $147.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BDXNHC
| Q4 25 | $25.3B | $1.1B | ||
| Q3 25 | $25.4B | $1.1B | ||
| Q2 25 | $25.5B | $1.0B | ||
| Q1 25 | $25.2B | $1.0B | ||
| Q4 24 | $25.2B | $980.2M | ||
| Q3 24 | $25.9B | $983.5M | ||
| Q2 24 | $25.9B | $945.8M | ||
| Q1 24 | $25.6B | $924.7M |
总资产BDXNHC
| Q4 25 | $54.8B | $1.5B | ||
| Q3 25 | $55.3B | $1.6B | ||
| Q2 25 | $54.9B | $1.6B | ||
| Q1 25 | $54.5B | $1.5B | ||
| Q4 24 | $54.7B | $1.5B | ||
| Q3 24 | $57.3B | $1.6B | ||
| Q2 24 | $55.6B | $1.3B | ||
| Q1 24 | $54.2B | $1.3B |
负债/权益比BDXNHC
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $16.8M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $6.4M |
| 自由现金流率自由现金流/营收 | 10.5% | 1.7% |
| 资本支出强度资本支出/营收 | 2.1% | 2.7% |
| 现金转化率经营现金流/净利润 | 1.72× | 0.68× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $148.6M |
8季度趋势，按日历期对齐
经营现金流BDXNHC
| Q4 25 | $657.0M | $16.8M | ||
| Q3 25 | $1.4B | $66.2M | ||
| Q2 25 | $1.2B | $62.8M | ||
| Q1 25 | $164.0M | $39.3M | ||
| Q4 24 | $693.0M | $12.8M | ||
| Q3 24 | $1.2B | $34.2M | ||
| Q2 24 | $1.3B | $50.7M | ||
| Q1 24 | $514.0M | $9.6M |
自由现金流BDXNHC
| Q4 25 | $549.0M | $6.4M | ||
| Q3 25 | $1.0B | $56.5M | ||
| Q2 25 | $1.0B | $52.6M | ||
| Q1 25 | $35.0M | $33.1M | ||
| Q4 24 | $588.0M | $4.6M | ||
| Q3 24 | $882.0M | $28.6M | ||
| Q2 24 | $1.1B | $42.8M | ||
| Q1 24 | $380.0M | $3.7M |
自由现金流率BDXNHC
| Q4 25 | 10.5% | 1.7% | ||
| Q3 25 | 17.0% | 14.8% | ||
| Q2 25 | 19.0% | 14.0% | ||
| Q1 25 | 0.7% | 8.9% | ||
| Q4 24 | 11.4% | 1.3% | ||
| Q3 24 | 16.2% | 8.4% | ||
| Q2 24 | 22.4% | 14.2% | ||
| Q1 24 | 7.5% | 1.2% |
资本支出强度BDXNHC
| Q4 25 | 2.1% | 2.7% | ||
| Q3 25 | 6.0% | 2.5% | ||
| Q2 25 | 3.2% | 2.7% | ||
| Q1 25 | 2.4% | 1.6% | ||
| Q4 24 | 2.0% | 2.2% | ||
| Q3 24 | 5.4% | 1.7% | ||
| Q2 24 | 3.6% | 2.6% | ||
| Q1 24 | 2.7% | 2.0% |
现金转化率BDXNHC
| Q4 25 | 1.72× | 0.68× | ||
| Q3 25 | 2.75× | 1.69× | ||
| Q2 25 | 2.12× | 2.65× | ||
| Q1 25 | 0.53× | 1.22× | ||
| Q4 24 | 2.29× | 2.10× | ||
| Q3 24 | 2.94× | 0.80× | ||
| Q2 24 | 2.66× | 1.89× | ||
| Q1 24 | 0.96× | 0.37× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
NHC
| Inpatient Services Segment | $333.7M | 86% |
| Homecare Services Segment | $40.0M | 10% |
| Other | $11.2M | 3% |
| National | $1.6M | 0% |
